INSM

InsmedNasdaqGS:INSM Stock Report

Market Cap

US$3.1b

7D

-4.5%

1Y

-19.0%

Updated

16 Sep, 2021

Data

Company Financials +
INSM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

INSM Overview

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.

Insmed Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Insmed
Historical stock prices
Current Share PriceUS$26.86
52 Week HighUS$22.00
52 Week LowUS$45.44
Beta2.25
1 Month Change15.18%
3 Month Change-7.70%
1 Year Change-19.05%
3 Year Change23.61%
5 Year Change79.07%
Change since IPO-83.72%

Recent News & Updates

Sep 10
Is Insmed (NASDAQ:INSM) Using Too Much Debt?

Is Insmed (NASDAQ:INSM) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

INSMUS BiotechsUS Market
7D-4.5%-0.4%-0.6%
1Y-19.0%25.7%33.6%

Return vs Industry: INSM underperformed the US Biotechs industry which returned 24.9% over the past year.

Return vs Market: INSM underperformed the US Market which returned 33.7% over the past year.

Price Volatility

Is INSM's price volatile compared to industry and market?
INSM volatility
INSM Beta2.25
Industry Beta1.03
Market Beta1

Stable Share Price: INSM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: INSM's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1988521Will Lewishttps://www.insmed.com

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders.

Insmed Fundamentals Summary

How do Insmed's earnings and revenue compare to its market cap?
INSM fundamental statistics
Market CapUS$3.10b
Earnings (TTM)-US$374.83m
Revenue (TTM)US$170.64m

18.1x

P/S Ratio

-8.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
INSM income statement (TTM)
RevenueUS$170.64m
Cost of RevenueUS$132.84m
Gross ProfitUS$37.80m
ExpensesUS$412.63m
Earnings-US$374.83m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-3.60
Gross Margin22.15%
Net Profit Margin-219.67%
Debt/Equity Ratio103.3%

How did INSM perform over the long term?

See historical performance and comparison

Valuation

Is Insmed undervalued compared to its fair value and its price relative to the market?

38.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: INSM ($26.86) is trading below our estimate of fair value ($43.58)

Significantly Below Fair Value: INSM is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: INSM is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: INSM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate INSM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: INSM is overvalued based on its PB Ratio (5.8x) compared to the US Biotechs industry average (3.2x).


Future Growth

How is Insmed forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

48.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: INSM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: INSM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: INSM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: INSM's revenue (40.3% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: INSM's revenue (40.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: INSM is forecast to be unprofitable in 3 years.


Past Performance

How has Insmed performed over the past 5 years?

-13.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: INSM is currently unprofitable.

Growing Profit Margin: INSM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: INSM is unprofitable, and losses have increased over the past 5 years at a rate of 13.8% per year.

Accelerating Growth: Unable to compare INSM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INSM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: INSM has a negative Return on Equity (-70.58%), as it is currently unprofitable.


Financial Health

How is Insmed's financial position?


Financial Position Analysis

Short Term Liabilities: INSM's short term assets ($1.0B) exceed its short term liabilities ($99.7M).

Long Term Liabilities: INSM's short term assets ($1.0B) exceed its long term liabilities ($599.1M).


Debt to Equity History and Analysis

Debt Level: INSM's debt to equity ratio (103.3%) is considered high.

Reducing Debt: INSM's debt to equity ratio has increased from 8.5% to 103.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: INSM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if INSM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Insmed current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate INSM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INSM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INSM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INSM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of INSM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Will Lewis (52 yo)

9yrs

Tenure

US$6,185,704

Compensation

Mr. William H. Lewis, also known as Will, J.D., M.B.A., has been Chief Executive Officer and President at Insmed Incorporated since September 11, 2012 and has been its Chairman of Board since November 6, 2...


CEO Compensation Analysis

Compensation vs Market: Will's total compensation ($USD6.19M) is about average for companies of similar size in the US market ($USD5.25M).

Compensation vs Earnings: Will's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: INSM's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: INSM's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.6%.


Top Shareholders

Company Information

Insmed Incorporated's employee growth, exchange listings and data sources


Key Information

  • Name: Insmed Incorporated
  • Ticker: INSM
  • Exchange: NasdaqGS
  • Founded: 1988
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.096b
  • Shares outstanding: 115.25m
  • Website: https://www.insmed.com

Number of Employees


Location

  • Insmed Incorporated
  • 700 US Highway 202/206
  • Bridgewater
  • New Jersey
  • 08807-1704
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/16 22:48
End of Day Share Price2021/09/16 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.